CAMBRIDGE, Mass., June 5 (UPI) -- Xanthus said Monday Symadex was well tolerated in a phase 1 study involving patients with advanced solid tumors.
The phase 1 results were presented at the American Society of Clinical Oncology meeting in Atlanta.
"Meeting our phase 1 safety endpoint is an important milestone that supports our continued advancement of Symadex in clinical trials for patients with advanced malignancies," said Richard Dean, CEO at Xanthus.
In the study, 22 patients received weekly intravenous infusions of Symadex for three weeks, followed by a week of rest. The dose was increased until dose limiting toxicity was reached.
The adverse events included transient neutropenia, nausea, asthenia, vomiting and diarrhea. Two cases of post-infusion fever occurred and resolved within 24 hours.
Symadex is now being studied in phase 2 trials in patients with metastatic colorectal cancer and metastatic breast cancer.
